RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by a bold mission—to treat inflammatory diseases and conquer cancer in our lifetime.

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with …

Our proprietary drug discovery and development engine has identified several immune drivers that have the ability to be “tuned up” or “tuned down” to modulate the immune system, either to …

Dec 23, 2024 · SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical …

Nov 11, 2024 · RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for …

Dec 23, 2024 · RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with significant …

RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and …

RAPT’s lead oncology drug candidate, FLX475, selectively inhibits the migration of immunosuppressive regulatory T cells (T reg) into tumors. In a Phase 1 clinical study in 104 …

RAPT Therapeutics (formerly FLX Bio) is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule …

RAPT Therapeutics is focused on the development of therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing our deep and proprietary expertise in …